Corrigendum on “Isorhamnetin augments the anti-tumor effect of capeciatbine through the negative regulation of NF-κB signaling cascade in gastric cancer” [Cancer Lett. 363 (1) (2015) 28–36]

Manu, K.; Shanmugam, M.; Ramachandran, L.; Li, F.; Siveen, K.; Chinnathambi, A.; Zayed, M.; Alharbi, S.; Arfuso, Frank; Kumar, Alan Prem; Ahn, K.; Sethi, G.

doi:10.1016/j.canlet.2018.01.003

Access Status

Fulltext not available

Authors

Manu, K.

Shanmugam, M.

Ramachandran, L.

Li, F.

Siveen, K.

Chinnathambi, A.

Zayed, M.

Alharbi, S.

Arfuso, Frank

Kumar, Alan Prem

Ahn, K.

Sethi, G.

Date

2018

Type

Journal Article

Metadata

Show full item record

Citation

Manu, K. and Shanmugam, M. and Ramachandran, L. and Li, F. and Siveen, K. and Chinnathambi, A. and Zayed, M. et al. 2018. Corrigendum on “Isorhamnetin augments the anti-tumor effect of capeciatbine through the negative regulation of NF-κB signaling cascade in gastric cancer” [Cancer Lett. 363 (1) (2015) 28–36]. Cancer Letters. 420.

Source Title

Cancer Letters

DOI

10.1016/j.canlet.2018.01.003

ISSN

0304-3835

School

School of Pharmacy and Biomedical Sciences

URI

http://hdl.handle.net/20.500.11937/67036

Collection

Curtin Research Publications

Abstract

© 2018 The authors regret that there was a typographical error in the title of the article “Capeciatbine” should be spelled as “Capecitabine”. The authors would like to apologize for any inconvenience caused.